- Augurex to sponsor the AS/axSpA Back Summit 2025, hosted by the Canadian Spondyloarthritis Association (CSA)
- Featuring SPINEstat™, a Health Canada-approved, first-in-class diagnostic blood test for the early and accurate detection of axial spondyloarthritis (axSpA).
Vancouver, Canada – June 16, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for autoimmune diseases, today announced it will sponsor the AS/axSpA Back Summit 2025, taking place on June 23 in Toronto. Hosted by the Canadian Spondyloarthritis Association (CSA), this national event brings together healthcare professionals across rheumatology, primary care, allied health, and patient advocacy to address the critical challenge of delayed axial spondyloarthritis (axSpA) diagnosis.
An estimated 500,000 Canadians are affected by axSpA, yet many face years-long delays in diagnosis. These delays often lead to irreversible damage and prolonged suffering, highlighting the urgent need for improved awareness and earlier detection.
As part of its commitment to advancing diagnostic innovation, Augurex will be on-site to highlight SPINEstat™, a Health Canada-approved, first-in-class blood test that detects Anti-14-3-3eta autoantibodies. SPINEstat is designed to aid in the early and accurate diagnosis of axial spondyloarthritis (axSpA), supporting faster access to appropriate care.
Join us at the AS/axSpA Back Summit 2025 to learn more about how Augurex is supporting earlier detection and better care for people living with axSpA.
For more details about the event, visit: Back Summit 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com